Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. TOPIC 386: NOVEL ORALLY BIOAVAILABLE PDE-CATENIN INHIBITOR CONCENTRATES IN LUNG FOR CANCER CHEMOPREVENTION

    SBC: ADT Pharmaceuticals, LLC            Topic: NCI

    This application is based on ADT Pharmaceuticalsdiscoveries thatthe cGMP degrading phosphodiesterase isozymephosphodiesteraseAPDEis overexpressed during early stages of tumorigenesisgenetic knockdown of PDEresults in selective apoptosis of tumor cells by activating cGMP PKG signalingandsmall molecule inhibitors of PDEinduce apoptosis by PKG phosphorylation of oncogeniccateninthereby suppressing Tc ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. STING Inhibitor Discovery for Rare and Common Autoimmune Diseases

    SBC: DISCOVERYBIOMED, INC.            Topic: NIAID

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Nitor TherapeuticsIncNitorProject Summary Abstract The over arching commercial goal for this Nitor TherapeuticsIncNitorand DiscoveryBioMedIncDBMcollaboration is to discover and validate Stimulator of Interferon Genes orSTINGinhibitor ligands in a novel high throughput screeningHTSand validation based Critical Path of bioassaysAberr ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Rodents Derived Synthetic Blood Brain Barrier Models for Chemical Toxicity Screening

    SBC: CFD Research Corporation            Topic: NIEHS

    AbstractThe overall goal of this study is to develop and demonstrate a novelpredictive in vitro organotypicD culture models of the blood brain barrierBBBderived from rodents for chemical toxicity screeningIn contrast with current Transwell based static and microfluidic assaysour commercially available SynBBB model enables real time visualization and quantitation of transport permeation under physi ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Enhanced endothelialization of nanomatrix coated flow diverter for intracranial aneurysms

    SBC: ENDOMIMETICS, LLC            Topic: NINDS

    Approximatelyof the population has unruptured cerebral aneurysmsapproximatelymillion people in the USAboutrupture per yearwith devastating consequencesAboutof patients with ruptured aneurysms dieandofwho survive have significant disabilitiesCoil embolization therapy is associated with a high rate of recurrenceFlow diverters are increasingly being used to cover the neck of the aneurysm providing mo ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    SBC: Siteone Therapeutics, Inc.            Topic: 105

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic painsuch as pain associated with chemotherapy induced peripheral neuropathythat targets an isoform of the voltage gated sodium ion channelNaVVoltage gated sodium channels are involved in the transmission of nociceptive signals from their site of origin in the periphe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Novel oral delivery system for subunit vaccine against ETEC

    SBC: FoodSource Lure Corporation            Topic: NIAID

    Project Summary Abstract Oral vaccines have the potential to make a revolutionary improvement in the quality of life in developing countriesSince these vaccines can be administered by community health workers who are not trained medical personnelthe number of people who can be immunized in a short period of time is drastically increased while the cost per patient is significantly loweredOral vacci ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Microfluidic Assay for Screening Vascular Cardiotoxicity

    SBC: CFD Research Corporation            Topic: NHLBI

    Abstract The overall objective of this study is to develop a novelpredictive in vitro platform for studying physiological responses of endothelium mediated human cardiomyocytes toxicity to therapeuticsThe proposed effort specifically responds to NHLBI Small Business Topics of Special Interest HLSA critical in vivo component lacking in conventional models used for cardiac toxicity is the absence of ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Inhibitors of cANGPTL4 for Pancreatic Cancer Therapeutics

    SBC: CFD Research Corporation            Topic: 102

    This project seeks to develop inhibitors of a novel pancreatic ductal adenocarcinomaPDACprotein targetPDAC remains one of the deadliest cancers with an average survival ofmonths for non resectable tumorsCurrentlya major obstacle in PDAC treatment is that the cells rapidly exhibit resistance to existing untargeted treatment regimens leaving patients with no further optionsStudies indicate that inhi ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Acoustic Enhanced Cell Culture

    SBC: RESODYN CORPORATION            Topic: 400

    This Small Business Innovation Research Phase I project will develop a prototype and then evaluate a novel device that utilizes low frequency sound energy to enhance cell culture productivityThe acoustic micromixing generated by the proposed device is compatible with cells and possesses the capability to substantially enhance the culture efficiency of cells cultured in typical culture vesselsThis ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough

    SBC: Siteone Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARYThe objective of our program is to develop a safe and effective therapeutic for chronic coughChronic coughor cough that persists for more than eight weeksis a condition that is often associated with diseases such as chronic obstructive pulmonary disorderCOPDasthmaidiopathic pulmonary fibrosisbronchiectasis or gastroesophageal reflux diseaseGERDIn other casesthe etiology is unknownCh ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government